**Core Concept**
Neutropenia after chemotherapy is a common side effect that increases the risk of infections. It occurs due to the suppression of the bone marrow's ability to produce neutrophils, a type of white blood cell crucial for fighting infections. The underlying principle being tested is the need for supportive care to manage neutropenia and prevent infections.

**Why the Correct Answer is Right**
The treatment of neutropenia after chemotherapy involves the administration of granulocyte-colony stimulating factor (G-CSF), also known as filgrastim. G-CSF stimulates the bone marrow to produce more neutrophils, thereby increasing the count and reducing the risk of infections. This is achieved by binding to specific receptors on the surface of bone marrow cells, which activates a signaling pathway that promotes the production and release of neutrophils.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because antibiotics are used to treat infections caused by bacteria, not to increase the neutrophil count. Antibiotics would not address the underlying cause of neutropenia.
**Option B:** This option is incorrect because erythropoietin is a hormone that stimulates the production of red blood cells, not white blood cells like neutrophils.
**Option C:** This option is incorrect because platelet transfusions are used to treat low platelet counts, not neutropenia.

**Clinical Pearl / High-Yield Fact**
It is essential to note that the administration of G-CSF should be initiated as soon as possible after chemotherapy to maximize its effectiveness in preventing neutropenia-related infections. Additionally, patients with severe neutropenia may require hospitalization and supportive care, such as antibiotics and transfusions, to manage their condition.

**Correct Answer:** D. G-CSF (Filgrastim)